# Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07323641/  
OnCo record `nct07323641` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of osimertinib and telisotuzumab vedotin in lung cancer, run by Jonsson Comprehensive Cancer Center, now recruiting.

## Summary

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07323641 by Jonsson Comprehensive Cancer Center, with a registry enrolment figure of 60 participants, started 2026-02-19 and due to reach its primary completion in 2027-02-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Survey Administration; Telisotuzumab Vedotin. Conditions listed: Lung Non-Small Cell Carcinoma. Primary outcome: Objective response rate (ORR); Progression free survival (PFS). Lung eligibility wording from the registry: "* Cytologically or histologically confirmed non small cell lung cancer (NSCLC), which is incurable with an activating and sensitizing EGFR mutation (e". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07323641
- Phase: 2
- Setting: A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib
- Sponsor: Jonsson Comprehensive Cancer Center
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07323641: https://clinicaltrials.gov/study/NCT07323641

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07323641.json